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ABSTRACT
Background: Cerebral autoregulation is often impaired after aneurysmal subarachnoid 
haemorrhage (aSAH). Dexmedetomidine is being increasingly used, but its effects on cerebral 
autoregulation in patients with aSAH have not been studied before. Dexmedetomidine could be a 
useful sedative in patients with aSAH as it enables neurological assessment during the infusion. 
The aim of this preliminary study was to compare the effects of dexmedetomidine on dynamic and 
static cerebral autoregulation with propofol and/or midazolam in patients with aSAH. 
Methods: Ten patients were recruited. Dynamic and static cerebral autoregulation were assessed 
using transcranial Doppler ultrasound during propofol and/or midazolam infusion and then during 
three increasing doses of dexmedetomidine infusion (0.7, 1.0 and 1.4 g/kg/h). Transient 
hyperaemic response ratio (THRR) and strength of autoregulation (SA) were calculated to assess 
dynamic cerebral autoregulation. Static rate of autoregulation (sRoR)% was calculated by using 
noradrenaline infusion to increase the mean arterial pressure 20 mmHg above the baseline. 
Results: Data from 9 patients were analysed. Compared to baseline, we found no statistically 
significant changes in THRR or sROR%.  THRR was (meanSD) 1.20 0.14, 1.170.13(p=0.93), 
1.140.09 (p=0.72) and 1.190.18 (p=1.0) and sROR% was 150.8984.37, 75.2227.75 (p=0.08), 
128.2558.35 (p=0.84) and 104.8236.92 (p=0.42) at baseline and during 0.7, 1.0 and 1.4  g/kg/h 
dexmedetomidine infusion, respectively. Dynamic SA was significantly reduced after 1.0 g/kg/h 
dexmedetomidine (p=0.02). 
Conclusions: Compared to propofol and/or midazolam, dexmedetomidine did not alter static 
cerebral autoregulation in aSAH patients, whereas a significant change was observed in dynamic 
SA. Further and larger studies with dexmedetomidine in aSAH patients are warranted. 
Editorial Comment:
There may be concern for effects of potent vasodilatory drugs on cerebral vascular tone and 
responsiveness in patients with intracranial injury.  The authors report here that cerebral blood 
flow autoregulation was unchanged in post- aneurysmal subarachnoid haemorrhage patients who 
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INTRODUCTION
Aneurysmal subarachnoid haemorrhage (aSAH) is a detrimental disease often affecting a relatively 
young population and leading to severe disability. Cerebral autoregulation maintains the cerebral 
blood flow constant despite changes in mean arterial pressure by changing cerebrovascular 
resistance. Dynamic and static autoregulation reflect rapid responses to changes in pressure 
pulsation and slow responses to changes in mean arterial pressure, respectively. 1 Previous studies 
have reported that impaired cerebral autoregulation in patients with aSAH predicts the 
development of radiological vasospasm and delayed cerebral ischemia (DCI); and may correlate 
with poor outcome. 2-4 
Dexmedetomidine is a selective 2-agonist which induces sedation, anxiolysis and analgesia with 
minimal respiratory depression. Importantly, it allows patient awakening despite uninterrupted 
infusion enabling frequent neurological evaluation. 5 These properties and potential 
neuroprotective effects make dexmedetomidine desirable in neurocritical care.6 While 
dexmedetomidine seems to attenuate dynamic cerebral autoregulation in healthy volunteers,7 its 
effects on cerebral autoregulation in aSAH patients are unknown. Thus, the primary aim of this 
preliminary study was to compare dynamic and static cerebral autoregulation in patients with 
aSAH under dexmedetomidine versus propofol and/or midazolam sedation. We did not aim to 
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METHODS
The study was conducted in the Intensive Care Unit in Turku University Hospital, Turku, Finland. 
The study protocol (EudraCT 2012-000068-11, ClinicalTrials.gov identifier NCT01664520) 
conformed to the revised Declaration of Helsinki8 and was approved by the ethical review board of 
the Hospital District of Southwest Finland (31/180/2012) and by the Finnish National Agency for 
Medicines. Written informed consent was obtained from the next of kin.
Patients aged 18-80 years suffering from aSAH and requiring sedation and mechanical ventilation 
after aneurysmal treatment (coiling or clipping) were included. aSAH patients not requiring 
sedation or mechanical ventilation were excluded. Other exclusion criteria were pregnancy, 
nursing women, sick sinus syndrome, carotid stenosis, heart rate < 50 beats/min, mean arterial 
pressure < 55 mmHg, baseline middle cerebral artery (MCA) flow velocity (VMCA) 120 cm/s 
suggesting vasospasm and clinical signs of DCI. 
All patients received intravenous nimodipine infusion and were treated according to Neurocritical 
Care Society recommendations with local modifications.9  ICP was measured continuously using 
intraparenchymal sensors, either Neurovent-PTO (Raumedic AG, Helmbrechts, Germany) or 
Codman ICP Monitoring system (DePuy Synthes, Wokingham, UK). Neurovent-PTO was used 
in seven patients whereas Codman was used in one patient.  Of the eight patients with 
intraparenchymal ICP catheter, four patients also had an external ventricular drainage (EVD) due 
to hydrocephalus. Two patients had only EVD and in those patients, cerebrospinal fluid was 
continuously drained and ICP was measured periodically.  Cerebral oxygenation was monitored 
continuously using bilateral near-infrared spectroscopy (NIRS) with INVOSTM cerebral oximetry. 
In patients with Neurovent-PTO, brain tissue oxygenation (PtiO2) was also monitored. 
Transcranial Doppler (TCD) was used to measure bilateral VMCA using 2 MHz-probes (Atys, 
Soucieu-en-Jarrest, France) fixed with a head frame.
Study protocol
First, static and dynamic autoregulation were assessed during a constant rate of propofol (2-5 
mg/kg/h) and/or midazolam infusion (0.03-0.3 mg/kg/h) (baseline). Thereafter propofol and/or 
midazolam infusion was stopped and dexmedetomidine (Dexdor ® Orion Oyj, Helsinki, Finland) 
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hours of dexmedetomidine infusion at constant rate (in order to reach a steady state), static and 
dynamic autoregulation were assessed again. While obtaining the steady dexmedetomidine state, 
all patients received 1-3 mg intravenous doses of oxycodone for analgesia at the discretion of the 
ICU nurse treating the patient. Next, dexmedetomidine infusion was increased to 1 g/kg/h for two 
hours following which, static and dynamic autoregulation were assessed. Finally, 
dexmedetomidine dose was increased to 1.4 g/kg/h for another two hours and autoregulation tests 
were performed once again (see Figure 1). After each period of two hours of dexmedetomidine 
infusion, arterial blood was sampled to measure the plasma dexmedetomidine concentration 
(details in supplementary material). During the autoregulation tests, no opioids or other drugs were 
administered. No blinding was performed. To avoid the effects of temperature, haemoglobin (Hb) 
and ventilation on cerebral blood flow velocity, these variables were kept constant throughout the 
study.
Dynamic autoregulation test
Dynamic autoregulation was assessed with transient hyperaemic response test (THRT) which is 
considered safe during the acute phase of SAH. 10-12 The common carotid artery was compressed 
for eight seconds while the ipsilateral MCA flow velocity (FV) was recorded before and after 
releasing compression. Two investigators were always present during the assessment; the 
compression of carotid artery was performed by the same investigator in all cases (MK) and the 
FV readings were manually recorded either by RT, MR, JP or AK. The adequacy of compression 
was assessed visually (a sudden decrease in VMCA with no further decrease). The test was accepted 
only when the hemodynamic parameters remained stable during the compression. The intervention 
was discontinued if there was sinus arrest or if intracranial pressure (ICP) increased above 20 
mmHg. When the carotid artery is compressed, a drop in perfusion pressure leads to distal 
cerebrovascular dilatation as a compensatory mechanism if autoregulatory mechanisms are active. 
Consequently, after releasing the compression, the VMCA increases beyond the pre-compression 
value leading to hyperaemic response. However, in case of impaired autoregulation, no 
cerebrovascular dilatation or transient hyperaemia will occur. 
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The baseline FV was systolic FV before compression. Due to overshoot phenomenon, the first 
cardiac cycle was ignored and the systolic FVhyperaemia was the average of the systolic FV of the 
second and third cardiac cycles after the compression. 11THRR was repeated three times on both 
hemispheres and there was at least 60 seconds interval between the measurements. The data was 
averaged from both hemispheres13 and considered normal if THRR was ≥1.09 and impaired if 
THRR was < 1.09. 10 
Strength of dynamic autoregulation (SA) was calculated as
𝑆𝐴 =
𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝐹𝑉ℎ𝑦𝑝𝑒𝑟𝑎𝑒𝑚𝑖𝑎 ∙  𝑀𝐴𝑃 𝑜𝑓 60 𝑚𝑚𝐻𝑔
𝑀𝐴𝑃 ∙  𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝐹𝑉𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
where systolic FVhyperaemia is the first flow velocity after the release of carotid compression and 
MAP of 60 mmHg represents the lower limit of autoregulation. MAP is the mean arterial pressure 
immediately before the THRT and FVbaseline is the flow velocity before carotid compression. 14 
SA value < 1 suggests under regulation and > 1 hyperregulation. 15 In the underregulated 
situation, cerebral blood vessels are already dilated and a decrease in blood pressure does 
not result in further dilation, whereas in hyperregulation the cerebral blood vessels dilate 
more than should be necessary. 15 
Static autoregulation test
Static autoregulation was tested by increasing the mean arterial pressure (MAP) by 20 mmHg with 
noradrenaline infusion while VMCA was continuously monitored with TCD. After the MAP had 
reached the desired level, the final VMCA was considered to be mean of the 20 min VMCA. 16 




If the percentage change of CVR equals to percentage change in MAP, there would be no change 
in FV, indicating intact autoregulation. 
Static rate of autoregulation (sRoR)% describes the change in cerebrovascular resistance (CVR) 
determined from the relation between cerebral blood flow velocity (CBFV) and changing cerebral 
perfusion pressure (CPP). It is calculated: 
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However, in those patients who had only EVD, we used MAP (as the CSF was continuously 
drained) in the formula and sROR% was calculated: 
𝑠𝑅𝑜𝑅% = 100 ×  (𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑉𝑚𝑐𝑎/𝐹𝑖𝑛𝑎𝑙 𝑉𝑚𝑐𝑎) ― (𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝐴𝑃/𝐹𝑖𝑛𝑎𝑙 𝑀𝐴𝑃)
 17÷ 1 ― (𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝐴𝑃/𝐹𝑖𝑛𝑎𝑙 𝑀𝐴𝑃)
sRoR of 100% or more indicates that autoregulation is completely intact, meaning that cerebral 
blood flow velocity is independent of cerebral perfusion pressure. sROR of 0% indicates that 
cerebral autoregulation is completely absent, and cerebral blood flow is linearly related to cerebral 
perfusion pressure. sROR of 50% is regarded as the cut off for failure of autoregulation. 
Accordingly, sRoR indicates quantitatively the stability of changes in cerebral blood flow when 
arterial blood pressure varies. 18
Statistical analysis
Data is presented as mean SD. All physiological and TCD parameters including autoregulation 
indices at various dexmedetomidine doses were compared to their respective baseline values 
recorded with propofol/midazolam.  Power analysis was not performed, and our sample size was 
based on previous similar autoregulation studies using TCD measurements. 19-21 The initial aim 
was to recruit 15 patients, but the recruitment was unexpectedly difficult (due to refusals of next of 
kin or suspicion of vasospasms in TCD) and very slow (from year 2013 to 2017). 
Repeated measures analysis of variance with Dunnett’s adjustment for multiple comparisons was 
used to compare autoregulation indices at various dexmedetomidine doses to their respective 
baseline values (propofol / midazolam). P < 0.05 was considered statistically significant. 
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RESULTS
Five male and five female patients with mean age of 58.4±10.5 years were recruited. One patient 
was excluded from dynamic and static autoregulation tests as she had no temporal acoustic 
window for the TCD, leaving 9 patients for the analysis. The demographic data for the patients is 
shown in Table 1.
Three patients had no temporal acoustic window on the left side and the Doppler measurements 
were done only on the right side. One patient expressed profound bradycardia during the dynamic 
test and was included only in the static test. As a baseline sedation, six patients had propofol 
infusion, two patients had midazolam infusion, one patient had midazolam infusion combined with 
propofol infusion and one patient did not have any sedation. The recruitment and the 
autoregulation tests took place during the first 24-48 hours after the surgical or endovascular 
treatment. The doses of oxycodone given to the patients between the measurements were 2.8±1.5 
mg after the commencement of the infusion of dexmedetomidine, 2.7±1.9 mg after 1.0 g/kg/h and 
2.3±1.4 mg after 1.4 g/kg/h dexmedetomidine. 
There was no significant difference between the Hb, PaO2 and PaCO2 values at each concentration 
of dexmedetomidine compared to baseline (Table 2). MAP and CPP were controlled with a 
noradrenaline-infusion. 
Overall, the SA was significantly lower after the 1.0  g/kg/h dose of dexmedetomidine compared 
to baseline (0.75 0.05, p=0.02) No other statistically significant difference was observed in THRR 
or SA (Figure 2, Table 3) with dexmedetomidine compared with propofol and/or midazolam.  
There was also no difference in the static parameters VMCA, CVR, sROR% (Figure 3) and PI 
(Figure 4) with dexmedetomidine compared with propofol and/or midazolam (Table 4).
One patient had impaired dynamic autoregulation at baseline, and it did not change with the 
administration of dexmedetomidine. This patient had impaired THRR values bilaterally. One 
patient had an impaired dynamic autoregulation on THRT after the initial dose of 
dexmedetomidine, but not after higher doses. One patient had THRR < 1.08 after the initial and the 
1.0 g/kg/h dose, but not after the highest dose, and one other patient showed an impaired dynamic 
autoregulation after the two highest doses. SA values were < 1 in all patients, and there was a 
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The patient, who had impaired dynamic autoregulation at baseline also had sROR% values < 50% 
throughout the study indicating impaired static autoregulation. Three other patients had sROR% < 
50% at some point during the study. 
There was no difference in cerebral oxygenation (PtiO2 and NIRS, Table 4) between baseline and 
different doses of dexmedetomidine.
Figure 5 shows a Bland-Altman plot to compare the agreement of the sROR% measurements 
using MAP or CPP.
We performed a subgroup analysis of the data for the five patients who had TCD measurements 
from both sides. We found no statistical differences in the autoregulation indices at any 
dexmedetomidine dose compared to baseline (data not shown). 
The cumulative dose of propofol before the commencement of dexmedetomidine was 6004±4165 
mg (N=7) and that of midazolam was 125.7±79 mg (N=3). The mean dexmedetomidine 
concentrations were 0.7± 0.22 ng/ml (after 0.7 g/kg/h for 2 hours), 1.19± 0.35 ng/ml (after 1.0 
g/kg/h for 2 hours) and 1.69± 0.39 ng/ml (after 1.4 g/kg/h for 2 hours). There was a trend 
towards a lower noradrenaline requirement with increasing dose of dexmedetomidine, but we 










This article is protected by copyright. All rights reserved
DISCUSSION
In this preliminary study where each patient with aSAH served as their own control, 
dexmedetomidine did not change static cerebral autoregulation indices compared to propofol 
and/or midazolam. SA was significantly lower after 1.0 g/kg/h dose of dexmedetomidine when 
compared to propofol and/or midazolam, although there were no significant changes in other 
dynamic autoregulation indices even with higher doses.
Cerebral autoregulation is often impaired in the first days after aSAH19 and is associated with poor 
outcome. 3,4,20 Previous studies have primarily concentrated on the dynamic component of cerebral 
autoregulation in aSAH patients. To the best of our knowledge, only one study has evaluated static 
autoregulation in aSAH and found that it was not impaired. 21 No previous studies have evaluated 
both elements of autoregulation in aSAH patients. We decided to test both dynamic and static 
cerebral autoregulation because they may be differently affected. For example, in ischemic stroke 
patients, while dynamic autoregulation is impaired for several days during the acute phase, static 
autoregulation remains unaffected . 22,23 Moreover, some anaesthetic agents impair dynamic but 
not static cerebral autoregulation. 24,25
There are multiple methods for investigating cerebral autoregulation. These include examining the 
recovery of CBFV after a rapid decrease of arterial blood pressure by using thigh cuff test26,27,28 
and examining spontaneous fluctuations in CBFV in relationship with MAP, ICP and brain tissue 
oxygenation (Cambridge Enterprise Ltd, University of Cambridge, UK). 29 We used the THRT for 
assessing dynamic autoregulation because it allows brief period of reduction in CBFV and is 
deemed safe in aSAH. Furthermore, we calculated SA, which is not affected by hemodynamic 
factors.15 Studying static cerebral autoregulation is traditionally performed by increasing MAP 
with a vasopressor and simultaneously measuring MAP and MCA flow velocities . 27 Modern 
techniques use PET scanning, which images CBF. 30 However, we preferred TCD to be able to 
perform the testing on the patient’s bedside and to avoid the need to transport intubated and 
sedated patients for imaging.
In healthy, anaesthetised patients, there is a correlation between both dynamic autoregulation tests 
(thigh cuff test, THRT and dynamic strength of autoregulation) and static autoregulation when 
static rate of autoregulation is used. 27,31However, various methods are probably not 
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Dynamic autoregulation has previously been shown to be impaired in healthy volunteers after 
administration of dexmedetomidine.7  In this study, we found that the SA was significantly lower 
after the 1.0 g/kg/h dose of dexmedetomidine compared to baseline, but not after the initial 0.7 
g/kg/h or the highest dose 1.4 g/kg/h. It is possible that the effect of dexmedetomidine on 
dynamic autoregulation may be dose dependent in this population.  Also, the ICP was not elevated 
in our patients and hence, they may have been less susceptible to any autoregulatory impairment 
with dexmedetomidine. Elevated ICP is known to correlate with impaired cerebral 
autoregulation.34 In previous volunteer studies, dexmedetomidine administration was associated 
with decrease in MAP, cardiac output and CBF.7,35 In contrast, we kept the blood pressure 
constant during dexmedetomidine infusion and THRT which may explain to some extent why there 
were no changes in most of the autoregulation indices. Dexmedetomidine induced reduction in 
CBF has been shown to be less in patients with traumatic brain injury if blood pressure is 
maintained at the pre-sedation level.36 We used noradrenaline infusion in maintaining and 
increasing MAP and CPP levels.37  Consequently, it is possible that autoregulatory impairment 
was not detected. It is possible that autoregulation was intact within the blood pressure range 
studied but may have been impaired outside of that range. 
During the first days after aSAH, many patients have low CBF regardless of vasospasm or DCI.38 
The global CBF in patients with Fisher grade 4 aSAH is lower than patients with Fisher grade 3, 
the impact of Fisher grade on CBF being more profound than the Hunt & Hess grades.38 Since 8 of 
our 10 patients had Fisher grade 4 aSAH, it is unlikely that the heterogeneity of Hunt & Hess 
grades had an effect on our findings.
Our study has important limitations. Firstly, the sample size is small and larger studies are needed 
to confirm our preliminary findings. Secondly, the baseline sedation was not the same in all the 
patients. While most patients had propofol-infusion, two had midazolam-infusion, one had both 
and one had no sedation. The patients were continuously sedated for a few days before 
administration of dexmedetomidine which can confound autoregulation status. Ogawa et al found 
that midazolam seems to improve whereas propofol seems to have no effect on dynamic cerebral 
autoregulation in healthy volunteers.39 In patients with traumatic brain injury, large, doses of 
propofol (more than 4 mg/kg/h) have been shown to impair static autoregulation . 30  We 
discontinued propofol 2 hours before the first and almost 6.5 hours before the last autoregulation 
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concentration to 20%.40 Therefore, the likelihood of residual propofol affecting cerebral 
autoregulation is small. Midazolam, on the other hand, may have had an effect on the dynamic 
autoregulation in our patients but only 3 patients were administered midazolam. Next, TCD only 
provides an estimate of CBF and it is assumed that the diameter of basal cerebral arteries varies 
only minimally with changes in MAP.41 42 This presumption has been recently challenged and  
TCD observations should be carefully interpreted for CBF. 43  Fourth, we performed the study 
during the first days after aSAH, before the DCI usually appears and it is possible that 
autoregulatory status may change over time. 
In conclusion, our preliminary findings indicate that in patients with aSAH, there was no difference 
in static cerebral autoregulation between dexmedetomidine and propofol and/or midazolam. The 
dynamic SA values, however, were significantly lower after 1.0 g/kg/h dose of dexmedetomidine 
when compared to propofol and/or midazolam. This finding suggests that a sudden decrease in 
arterial blood pressure in aSAH patients during dexmedetomidine sedation may not be desirable. 
These findings warrant further studies with larger sample size.  
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PaCO2 PaO2 and Haemoglobin (Mean ± SD) at baseline and at different doses of 
dexmedetomidine. There were no statistically significant changes at different doses of 
dexmedetomidine compared to baseline.  
Table 3. 
The indices for dynamic cerebral autoregulation at baseline (Propofol and/or Midazolam) and at 
different doses of dexmedetomidine (Dex). 
Table 4.
The indices for static cerebral autoregulation at baseline (Propofol and/or Midazolam) and at 
different doses of dexmedetomidine (Dex); initial states the baseline values before the 
augmentation of MAP and final states the values during increased MAP. The results during each 
dose of dexmedetomidine (Dex) were compared to baseline. PI, sROR% and VMCA are reported as 
an averaged value for both sides. The table also shows the brain tissue oxygenation, PtiO2, and 
near infrared spectroscopy (NIRS) values during baseline and each dose of dexmedetomidine. The 




Boxplot for dynamic autoregulation indices, THRR and SA, at baseline (propofol/midazolam) and 
at each dose of dexmedetomidine. Boxes represent lower quartiles, medians and upper quartiles, 
whiskers represent 1.5 x inert-quartile ranges below and above the lower and upper quartiles, 
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Boxplots for static rate of autoregulation, sROR%, calculated using MAP or CPP at baseline 
(propofol/midazolam) and at each dose of dexmedetomidine. Boxes represent lower quartiles, 
medians and upper quartiles, whiskers represent 1.5 x inert-quartile ranges below and above the 
lower and upper quartiles, respectively.
Figure 4. 
Individual values for pulsatility index, PI, at baseline (propofol/midazolam) and at each dose of 
dexmedetomidine. 
Figure 5.
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Table 1. Demographics of the patients that were included in the analysis. Data is 
presented as mean +/- SD.  
 
  
Age (yr.) 58.1 ± 11.1 
Height (cm) 173.4 ± 8.2 
Weight (kg) 74.8 ± 11.4 
Sex (male/female) 5 / 4 
  
GCS at admission (grade) (n) 


















ICA (dx/sin) 3 (2/0) 
MCA (dx/sin) 4 (2/2) 
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Coiling 7 
Coiling and stenting 0 
Clipping 2 
  











Hypertension (yes/no) 2/7 
Diabetes (yes/no) 0/9 
*The one excluded patient was female, 
61 years old, had GCS 6 at admission, 
Fisher 4, Hunt&Hess 4, had ICA l.sin 
aneurysm that was treated with coils 
and stent three days after rupture,, 



















Table 2. PaCO2 PaO2 and Haemoglobin (Mean ± SD) at baseline and at different doses of dexmedetomidine (Dex). There were no statistically 
significant changes at different dexmedetomidine doses compared to baseline.   
 
 
 Propofol Dex 0.7 p-value Dex 1.0 p-value Dex 1.4 p-value 
PaCO2 (mmHg) 37.3 ± 2.3 36.2 ± 2.6 0.62 35.4 ± 2.5 0.21 35.0 ± 2.3 0.10 
PaO2 (mmHg) 132.4 ± 37.3 149.7 ± 57.7 0.82 152.7 ± 59.1 0.75 151.1 ± 62.2 0.79 















Table 3. The indices for dynamic cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different doses of dexmedetomidine (Dex). THRR = 
transient hyperemic response ratio, SA = strength of autoregulation. 
 
  
 Baseline Dex 0.7 p-value Dex 1.0 p-value Dex 1.4 p-value 
THRR both 1.20 0.14 1.170.13 0.93 1.140.09 0.72 1.190.18 1.0 
SA both 0.890.13 0.800.12 0.15 0.750.05 0.02 0.780.08 0.07 
 
Table 4. The indices for static cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different doses of dexmedetomidine (Dex); 
initial states the baseline values before the augmentation of MAP and final states the values during increased MAP. The results during each dose 
of dexmedetomidine were compared to baseline. PI, sROR% and VMCA are reported as an averaged value for both sides. The table also shows the 
brain tissue oxygenation, PtiO2, and near infrared spectroscopy (NIRS) values during baseline and each dose of dexmedetomidine. The NIRS 
values are mean values of both sides. No significant difference was seen between the doses. MAP=mean arterial pressure; CPP = cerebral 
perfusion pressure; ICP = intracranial pressure; CVR=cerebrovascular resistance; sROR=static rate of autoregulation; PI=pulsatility index; 




 Baseline Dex 0.7 p-value Dex 1.0 p-value Dex 1.4 p-value 
MAP mmHg 
initial 
80.7010.51 87.509.0 0.22 88.907.99 0.11 89.107.72 0.10 
MAP mmHg 
final 
98.4011.08 104.8010.00 0.38 109.5010.05 0.05 109.009.88 0.07 
MAP% 21.705.12 20.604.11 0.90 23.104.18 0.81 22.303.80 0.98 
CPP mmHg 
initial 
78.686.77 79.808.92 0.99 80.919.16 0.91 82.398.41 0.71 
CPP mmHg 
final 
91.156.79 97.239.11 0.34 100.537.38 0.08 101.159.37 0.06 
CPP mmHg 16.097.22 22.114.71 0.22 24.868.55 0.47 23.046.88 0.14 
ICP mmHg 
initial 
8.935.88 9.604.77 0.99 9.285.00 1.00 9.704.84 0.98 
ICP mmHg  
final 
9.556.18 9.564.85 1.00 8.844.90 0.99 9.885.50 1.00 
CVR% 22.6614.26 15.027.18 0.41 22.2611.52 0.99 19.0913.39 0.86 
sROR% (CPP) 150.8984.37 75.2227.75 0.08 128.2558.35 0.84 104.8236.92 0.42 
sROR% 
(MAP) 
110.0177.97 80.4533.63 0.55 91.7835.23 0.82 89.7954.82 0.77 




67.5024.50 64.6721.38 0.98 60.2818.57 0.81 60.3319.40 0.82 
VMCA cm/s 
final 
66.6322.17 68.3322.72 1.00 61.0017.94 0.90 62.6722.43 0.96 
PtiO2 mmHg 
initial 
24.914.8 22.718.5 0.99 22.518.3 0.99 22.917.7 0.99 
PtiO2 mmHg 
final 
24.916 24.318.9 1.0 23.719.3 1.0 24.618.6 1.0 
NIRS % initial 
mean   
71.510.4 7211 1.0 69.711.5 0.97 69.510.5 0.96 
NIRS % final 
mean 













Static and dynamic 
autoregulation
Stop propofol and/or 
midazolam
Dexmedetomidine 0.7 g/kg/h 
2 hours
Static and dynamic 
autoregulation   
Dexmedetomidine  1.0 g/kg/h 
2 hours
Static and dynamic 
autoregulation   
Dexmedetomidine  1.4 g/kg/h 
2 hours
Static and dynamic 
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